-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $31

Benzinga·04/08/2026 12:48:27
Listen to the news
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $37 to $31.